TOR Pathway

Fuatilia
Scientist examining extended-lifespan yeast cells under microscope with rapalink-1 cancer drug vial, illustrating anti-aging breakthrough.
Àwòrán tí AI ṣe

Next-generation cancer drug shows anti-aging effects in yeast

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

Researchers at Queen Mary University of London have found that rapalink-1, an experimental TOR inhibitor being investigated for cancer therapy, extends the lifespan of fission yeast. The study also uncovered a role for agmatinases in regulating the TOR pathway through a metabolic feedback loop, suggesting potential links between diet, gut microbes, and aging.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ